Medarex shares rise on surprising cancer study

Shares of Medarex shot up 17 percent after investigators at the Mayo Clinic say they were startled by the level of success seen in a trial of a monoclonal antibody for prostate cancer. Two of the men with advanced, inoperable cases of prostate cancer are now reported to be cancer free after the drug ipilimumab shrank their tumors to the point that physicians could operate on them. And surgery is rarely an option for patients whose cancer has spread beyond the prostate.  Another 20 patients showed improvements and are being monitored.

The results prompted the researchers to plan another trial that will test a higher dose of the drug. "Our surgeons had never seen this happen before and we were really taken by surprise," said Dr. Eugene Kwon. "This is one of the holy grails of prostate cancer research. We've been looking for this for years."

"I had never seen anything like this before. I had a hard time finding the cancer," Dr. Michael Blute told the BBC. "At one point the pathologist (who was working during surgery) asked if we were sending him samples from the same patient."

- read the story from the BBC
- read the Dow Jones report

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.